The significant progresses recently achieved in the treatment of gastric, pancreatic and liver cancers have led clinicians to evaluate the opportunity to interrupt first-line treatments before disease progression and to consider maintenance therapies. In colorectal cancer, this strategy has produced remarkable advances, and patients whose disease is controlled after a few months of upfront therapy may derive clinical benefit and enjoy improved quality of life from continuing a less intensive treatment or early shifting to another, well-tolerated regimen. If the concept of maintenance may be applicable to other gastrointestinal malignancies is currently unknown, but the evidence is rapidly emerging.
To cite this article
The concept of maintenance: may we move it to gastric, pancreatic and liver cancers?
WCRJ 2016; 3 (2): e713
Submission date: 10 May 2016
Revised on: 16 May 2016
Accepted on: 26 May 2016
Published online: 29 Jun 2016
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.